A pharmaceutical-grade L-glutamine developed by Emmaus Life Sciences reduced the frequency of sickle cell crises and hospitalizations in a Phase III clinical trial, but questions remain about the commercial market for a product that's available as an over-the-counter supplement.
Emmaus spokesman Matt Sheldon told Scrip that the purity, strength and quality of the company's L-glutamine formulation are what makes...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
